Drug Trial Radar · NCT06799000
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
588
Actual
Start
Jan 31, 2025
Primary completion
May 17, 2027
Study completion Oct 4, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Conditions
- Hidradenitis Suppurativa
Interventions
Remibrutinib Dose ADrug
Remibrutinib Dose A (oral)
Remibrutinib Dose BDrug
Remibrutinib Dose B (oral)
Placebo 1Drug
Placebo matching to remibrutinib Dose A (oral)
Placebo 2Drug
Placebo matching to remibrutinib Dose B (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16Time frame: Week 16
Locations
139 sites in 20 countries. Site status is shown where the registry gives one.
Medical Dermatology Specialists
Phoenix, Arizona
Johnson Dermatology
Fort Smith, Arkansas
Arkansas Research Trials
North Little Rock, Arkansas
Cheryl Effron MD Inc
Anaheim, California
Physioseq
Sacramento, California
Olive View UCLA Medical Center
Sylmar, California
Clinical Trials Research Institute
Thousand Oaks, California
Howard University College of Medicine
Washington D.C., District of Columbia
Florida Academic Centers Research and Education LLC
Coral Gables, Florida
University of MiamiHealth System
Miami, Florida
Ziaderm Research LLC
North Miami Beach, Florida
Revival Research Institute LLC
Evans, Georgia
Gwinnett Clinical Research Center
Snellville, Georgia
Immunology-Rheumatology Research
Suwanee, Georgia
Illinois Dermatology Institute
Chicago, Illinois
Dawes Fretzin Clinical Rea Group
Indianapolis, Indiana
Equity Medical LLC
Bowling Green, Kentucky
Dermat. and Adv. Aesthetics
Lake Charles, Louisiana
Michigan Center for Rsrch Company
Clarkston, Michigan
Henry Ford Hospital
Detroit, Michigan
Revival Research Institute
Troy, Michigan
University of Mississippi Med Ctr
Jackson, Mississippi
Care Access Hoboken
Hoboken, New Jersey
Forest Hills Dermatology Group
New York, New York
Icahn School Of Med At Mount Sinai
New York, New York
Skinsearch of Rochester Inc
Rochester, New York
OnSite Clinical Solutions LLC
Huntersville, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina
Unity Clinical Research
Oklahoma City, Oklahoma
Essential Medical Research
Tulsa, Oklahoma
UP Medical Center H System
Pittsburgh, Pennsylvania
Medical University of South Carolina MUSC
Charleston, South Carolina
Advanced Research Experts
Nashville, Tennessee
Bellaire Dermatology Associates
Bellaire, Texas
RFSA Dermatology
San Antonio, Texas
Virginia Clinical Research
Norfolk, Virginia
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.